Effective treatment with Gilteritinib-based regimens for FLT3-mutant extramedullary relapse in acute promyelocytic leukemia

References

• Grignani F, Ferrucci PF, Testa U, et al. The acute promyelocytic leukemia-specific PML-RARα fusion protein inhibits differentiation and promotes survival of myeloid precursor cells. Cell. 1993;74(3):423–31. doi:10.1016/0092-8674(93)80044-F
   PubMed Web of Science ®Google Scholar
• Madan V, Shyamsunder P, Han L, et al. Erratum: comprehensive mutational analysis of primary and relapse acute promyelocytic leukemia. Leukemia. 2016;30(12):2430. doi:10.1038/leu.2016.237
   PubMed Web of Science ®Google Scholar
• Riva L, Ronchini C, Bodini M, et al. Erratum: acute promyelocytic leukemias share cooperative mutations with other myeloid-leukemia subgroups. Blood Cancer J. 2014;4(3):e195. doi:10.1038/bcj.2014.19
   PubMedGoogle Scholar
• Barragan E, Montesinos P, Camos M, et al. Prognostic value of FLT3 mutations in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy. Haematologica. 2011;96(10):1470–7. doi:10.3324/haematol.2011.044933
   PubMed Web of Science ®Google Scholar
• Schnittger S, Bacher U, Haferlach C, et al. Clinical impact of FLT3 mutation load in acute promyelocytic leukemia with t(15;17)/PML-RARA. Haematologica. 2011;96(12):1799–807. doi:10.3324/haematol.2011.049007
   PubMed Web of Science ®Google Scholar
• Callens C, Chevret S, Cayuela JM, et al. Prognostic implication of FLT3 and Ras gene mutations in patients with acute promyelocytic leukemia (APL): a retrospective study from the European APL Group. Leukemia. 2005;19(7):1153–60. doi:10.1038/sj.leu.2403790
   PubMed Web of Science ®Google Scholar
• Thirugnanam R, George B, Chendamarai E, et al. Comparison of clinical outcomes of patients with relapsed acute promyelocytic leukemia induced with arsenic trioxide and consolidated with either an autologous stem cell transplant or an arsenic trioxide-based regimen. Biol Blood Marrow Transplant. 2009;15(11):1479–84. doi:10.1016/j.bbmt.2009.07.010
   PubMed Web of Science ®Google Scholar
• de Botton S, Sanz MA, Chevret S, et al. Extramedullary relapse in acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. Leukemia. 2006;20(1):35–41. doi:10.1038/sj.leu.2404006
   PubMed Web of Science ®Google Scholar
• He Z, Tao S, Deng Y, et al. Extramedullary relapse in lumbar spine of patient with acute promyelocytic leukemia after remission for 16 years: a case report and literature review. Int J Clin Exp Med. 2015;8(12):22430–4.
   PubMed Web of Science ®Google Scholar
• Duminuco A, Maugeri C, Parisi M, et al. Target Therapy for Extramedullary Relapse of FLT3-ITD Acute Myeloid Leukemia: emerging Data from the Field. Cancers (Basel). 2022;14(9):2186. doi:10.3390/cancers14092186
   PubMed Web of Science ®Google Scholar
• Yanada M. Treatment for relapsed acute promyelocytic leukemia. Ann Hematol. 2022;101(12):2575–2582. doi:10.1007/s00277-022-04954-0
   PubMed Web of Science ®Google Scholar
• Sanz MA, Fenaux P, Tallman MS, et al. Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet. Blood. 2019;133(15):1630–1643. doi:10.1182/blood-2019-01-894980
   PubMed Web of Science ®Google Scholar
• Ganzel C, Douer D. Extramedullary disease in APL: a real phenomenon to contend with or not? Best Pract Res Clin Haematol. 2014;27(1):63–8.
   PubMed Web of Science ®Google Scholar
• Breccia M, Loglisci G, Loglisci MG, et al. FLT3-ITD confers poor prognosis in patients with acute promyelocytic leukemia treated with AIDA protocols: long-term follow-up analysis. Haematologica. 2013;98(12):e161–3. doi:10.3324/haematol.2013.095380
   PubMed Web of Science ®Google Scholar
• Beitinjaneh A, Jang S, Roukoz H, et al. Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations in acute promyelocytic leukemia: a systematic review. Leuk Res. 2010;34(7):831–6. doi:10.1016/j.leukres.2010.01.001
   PubMed Web of Science ®Google Scholar
• Lucena-Araujo AR, Kim HT, Jacomo RH, et al. Internal tandem duplication of the FLT3 gene confers poor overall survival in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based chemotherapy: an International Consortium on Acute Promyelocytic Leukemia study. Ann Hematol. 2014;93(12):2001–10. doi:10.1007/s00277-014-2142-9
   PubMed Web of Science ®Google Scholar
• Picharski GL, Andrade DP, Fabro A, et al. The impact of Flt3 gene mutations in acute promyelocytic leukemia: a meta-analysis. Cancers (Basel). 2019;11(9):1311. doi:10.3390/cancers11091311
   PubMed Web of Science ®Google Scholar
• Röllig C, Serve H, Hüttmann A, et al. Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial. Lancet Oncol. 2015;16(16):1691–9. doi:10.1016/S1470-2045(15)00362-9
   PubMed Web of Science ®Google Scholar
• Dumas PY, Raffoux E, Berard E, et al. Gilteritinib activity in refractory or relapsed FLT3-mutated acute myeloid leukemia patients previously treated by intensive chemotherapy and midostaurin: a study from the French AML Intergroup ALFA/FILO. Leukemia. 2023;37(1):91–101. doi:10.1038/s41375-022-01742-7
   PubMed Web of Science ®Google Scholar
• Perrone S, Ortu La Barbera E, Viola F, et al. A relapsing meningeal acute myeloid leukaemia FLT3-ITD+ responding to gilteritinib. Chemotherapy. 2021;66(4):134–138. doi:10.1159/000518356
   PubMed Web of Science ®Google Scholar
• Vignal N, Kelly L, Lengline E, et al. Favorable pharmacokinetics and pharmacodynamics properties of Gilteritinib in cerebrospinal fluid: a potential effective treatment in relapsing meningeal acute myeloid leukaemia FLT3-ITD patients. Haematologica. 2023;108(9):2531–2534. doi:10.3324/haematol.2022.282596
   PubMedGoogle Scholar
• Kida M, Kuroda Y, Kido M, et al. Successful treatment with gilteritinib for isolated extramedullary relapse of acute myeloid leukemia with FLT3-ITD mutation after allogeneic stem cell transplantation. Int J Hematol. 2020;112(2):243–248. doi:10.1007/s12185-020-02855-4
   PubMed Web of Science ®Google Scholar
• Cicconi L, Breccia M, Franceschini L, et al. Prolonged treatment with arsenic trioxide (ATO) and all-trans-retinoic acid (ATRA) for relapsed acute promyelocytic leukemia previously treated with ATRA and chemotherapy. Ann Hematol. 2018;97(10):1797–1802. doi:10.1007/s00277-018-3400-z
   PubMed Web of Science ®Google Scholar
• Gill H, Yim R, Lee HKK, et al. Long-term outcome of relapsed acute promyelocytic leukemia treated with oral arsenic trioxide-based reinduction and maintenance regimens: a 15-year prospective study. Cancer. 2018;124(11):2316–2326. doi:10.1002/cncr.31327
   PubMed Web of Science ®Google Scholar